Edgewise Touts Pan-Muscular Dystrophy Plans Following Early Promise In Becker
The US firm released promising interim data from a mid-stage Becker muscular dystrophy trial, claiming success here could translate to Duchenne as it unveiled plans for more studies across similar conditions.
You may also be interested in...
Biopharma stock prices overall are trending down again, but standout firms are raising cash, including the first company to price an IPO over $100m since May, Third Harmonic. Also, Sarepta and Alnylam launched large note offerings, totaling $1bn and $900m, respectively.
The US biotech’s lead candidate missed the mark in a Phase III hospital-related pneumonia trial due to low recruitment affected by macroeconomic headwinds but analysts retain high hopes for another upcoming study.
The UK biotech will use the funds to advance the development of its first-in-class ERAP1 inhibitor, which could circumvent the limitations of poor tumor visibility and T cell exhaustion.